Biotechnology · Watertown, Massachusetts, United States
$36.47
-2.17% (-$0.81)2026-08-24
Smart-Money SignalNeutral · 46/100— Insiders are net sellers over 90 days (-$32K, 5 sales vs 5 buys)
Net Income-$22.3M
EPS$-2.52
Market Cap$701.5M
Price Performance
Historical data including institutional events
Company Profile
A
Alise Reicin
CEO & Executive Director
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs).
It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.
The companyâs lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin.
It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators.
The company is headquartered in Watertown, Massachusetts.
